FDA Drug Approval Pipeline: Key New Therapies Expected This Year

What New Drugs Are Expected to Receive FDA Approval?

The FDA's Center for Drug Evaluation and Research (CDER) approved 50 novel drugs in 2024, continuing a trend of robust new drug approvals. The current year's pipeline includes several high-profile candidates that could address major unmet needs. Oncology remains the single largest category, with new targeted therapies and antibody-drug conjugates under review for various solid tumors and hematologic malignancies.

Beyond cancer, the metabolic disease space is particularly active. New insulin formulations, GLP-1 receptor agonists for expanded indications, and novel oral agents for type 2 diabetes are among the therapies with pending FDA decisions. Rare disease treatments — often benefiting from orphan drug designation and accelerated pathways — also make up a significant share of the pipeline, reflecting the FDA's continued commitment to expediting therapies for underserved patient populations.

How Does the FDA Expedite Reviews for Important New Therapies?

The FDA has established several mechanisms to accelerate drug development and review. Breakthrough Therapy Designation, introduced under the FDA Safety and Innovation Act of 2012, is granted when preliminary clinical evidence indicates a drug may demonstrate substantial improvement over existing treatments. Drugs with this designation receive intensive FDA guidance and may have their review timelines significantly shortened. Priority Review reduces the standard review clock from approximately 10 months to 6 months for drugs that offer meaningful therapeutic advances.

Accelerated Approval allows drugs to be approved based on surrogate endpoints — biomarkers or other measures that are reasonably likely to predict clinical benefit — rather than waiting for definitive outcomes data. This pathway has been especially important in oncology, where tumor response rates can support initial approval while confirmatory trials continue. The FDA has also increasingly used Real-Time Oncology Review and Project Orbis to further streamline cancer drug evaluations, sometimes issuing approvals ahead of the scheduled action date.

What Should Patients and Clinicians Know About Newly Approved Drugs?

When a new drug receives FDA approval, it does not immediately become widely available. Insurance formulary decisions, pharmacy stocking, and clinician familiarity all influence how quickly patients can access a newly approved therapy. Specialty drugs — particularly those for cancer and rare diseases — may require prior authorization and can carry significant out-of-pocket costs even with insurance coverage. Patient assistance programs from manufacturers can help bridge the gap, but navigating these systems takes time.

Clinicians should also be aware that pivotal trial populations may not fully represent the patients they see in practice. Post-marketing surveillance through the FDA's Adverse Event Reporting System (FAERS) often reveals side effects not captured during clinical trials, which enrolled carefully selected patient populations. The FDA may require Risk Evaluation and Mitigation Strategies (REMS) for certain drugs, adding additional monitoring and prescribing requirements designed to ensure that the benefits outweigh the risks in real-world use.